A multi-center randomized phase II clinical study of bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for Chinese patients with metastatic colorectal cancer
Crossref DOI link: https://doi.org/10.1007/s12032-014-0325-9
Published Online: 2014-12-07
Published Print: 2015-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Cao, Ranhua
Zhang, Shuai
Ma, Dedong
Hu, Likuan
Text and Data Mining valid from 2014-12-07
